Sapan Ghai, CCO at Sovereign Metals, discusses their superior graphite test results. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Stoney - also noticed the change in tone regarding progressing SRA 737 in that Dilly omitted ‘ non dilutive funding’
‘In June 2019, Sierra announced it was exploring non-dilutive strategic options to support the next stages of development of SRA737. Sierra appointed a new Chief Executive Officer, Dr Stephen Dilly, on 1 June 2020. In the notes to Sierra's most recent 10-Q Quarterly Report, dated 6 August 2020, it stated that it is exploring options to support the continued development of SRA737. ‘
the interest is there - and also note partnerS not a partner...
we just need to provide the data to show our molecules are all that... basic due diligience from pharmas especially as these molecules wont come cheap...
hi stoney
thats the way i also read into it...
SAR are gathering all the data for potential licencees--
Stoney, I like your forensic approach to disecting what Sareum are really saying! Good post with some very valid points. I think we would all welcome some plain speak and actual facts from the company on Friday. Waffles are for breakfast not for RNS' and presentations. Good luck, Brighty
Can we see a 1p prior to Father Tim doing his stuff on good Friday.
Good luck, this is the week of the storms.
Hi All - there is a lot going on for sure.
As with most information from SAR we have to read a few times and look for the subtle inferences. The one that caught my eye was mentioned below by another poster re the selectivity of our TYK2s......”In addition, both programmes represent unique licensing opportunities for pharmaceutical partners as there are currently no marketed products with the selectivity profile of these molecules”.
Furthermore, these 2 bullet points:
Build a robust preclinical data package to support ongoing partnering activities.
· Continue and advance initial discussions with potential partners to secure commercial licences for its assets when they reach late preclinical or early clinical stages.
The end game is coming ladies and gents.......
GLA
As of June last year there were still 22 subjects still on trial with some being on treatment for 11 + months fast forward a further 14 months and the current data now must be extremely compelling with patients still on trial. GLA
Thoth, we know Sierra have only got until the end of August to come up with a plan for 737 or they risk ICR taking back control. All eyes on SRRA this week and as you say it could be expanded trials and who knows maybe a co-development partner coming in, if that's the case my money would be on Gilead.
My personal view on SRRA fundraise.
1. 50% dilution and the shareprice hasnt dropped. Therefore the funders have been told something tasty is coming
2. SRRAs good points are around genetic selection of candidates and data analysis.
3. Validation of this would be continuation of 737 trial. In licencing a new product would not be credible
4. SRRA had a year and a half's money already. No need to raise at this point, andcertainly no more than 40m to complete momo trial
5. My guess (and it is only that), that it is not just anogenital, but possibly another indication (ovarian ??) and a parp combo trial. i.e 737 goes forward in several indications. Have to wait and see. and an LA based fund investing, when we dont fit the profile of their other investments (the likes of Accenture and Heineken) seems odd. My suspicious mind is the SRRA funding briefings percolated in the investment community and SAR seemed an appropriate bet off the back of. We will have to wait and see as ever.
Don't think there was anything in the RNS to scare the new investor, quite the reverse. I'd expect to see them pick up some more on this or any further dip. Their investment strategy as outlined in the prospectus is longer term. DYOR. S